The Studio365 mobile app by Live365 mobile app enables broadcasters to manage their radio stations anywhere they go. With the Studio365 mobile app you can: • Create, preview, and manage your Shout Out Messages • Set and update your pre-rolls and station ID messages • Update your profile including title, image, description, etc. • Check your listener stats in real time • Listen and share your station anywhere New features coming soon To
use the Studio365 app, a Live365 broadcasting account is required. To
learn more about broadcasting with Live365, and to get a free 7 day
personal broadcasting trial using the Live365 platform, visit
http://www.live365.com/dj
For the millions who suffer from Gastroesophageal Reflux Disease (GERD), a study published today in the New England Journal of Medicine (NEJM) provides clinical evidence of safety and effectiveness for a new, FDA-approved medical device. Torax Medical’s LINX® Reflux Management System was studied in a controlled, prospective, multicenter trial involving 14 U.S. and European medical centers as part of the FDA pre-market approval process. The patients were evaluated before and after treatment to determine the effect of the LINX System on their GERD using pre-defined success criteria, which included reduction of esophageal acid, improvement in quality of life and elimination of reflux medications.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60077-torax-medical-linx-reflux-management-system-clinical-study-published
People of all ages and levels are welcome to try out our specialized and customized training programs as part of our 30 Day Free Trial. The quality of our curriculum and instruction, the reliability, professionalism and appearance of our academy.
SIRO Clinpharm, a leading full service clinical research organization, unveiled its new brand identity on Friday. The new look affirms the recent transformation in the company’s business strategy.
“With the vast experience garnered over the past 16 years, SIRO was set to take a leap forward. With its customer centric leadership, we have built depth in various areas of competencies, leveraging our 4 pillars – people, processes, technologies and solutions,” said Dr. Gautam Daftary, founder and chairman, SIRO Clinpharm.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58672-SIRO-Clinpharm-unveils-new-brand-identity
Reproductive Medicine Associates of New Jersey (http://www.rmanj.com) today presented interim findings from its BEST (Blastocyst Euploid Selective Transfer) trial, the first well-controlled clinical trial comparing in vitro fertilization (IVF) pregnancy rates in a group of women receiving a single embryo transfer (SET) with comprehensive chromosome screening (CCS) with a group receiving traditional morphology-based double embryo transfer (DET). The findings were presented at the American Society for Reproductive Medicine 68th Annual Meeting in San Diego, October 20-24, 2012.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58883-rmanj-best-trial-results-ivf-pregnancy-rates-women-asrm-annual-meeting
http://FreeGames24-7.com Video Games? We Got Games! Free Unlimited PC Play! Start your One Month Free Trial Here. You're gonna love it or cancel with no cost or obligation.
Truvia®, the #1 natural zero calorie sweetener, announced the launch of a multimillion dollar integrated marketing campaign, “From Nature. For Sweetness.” The new creative campaign, kicked off on September 24th, will further drive consumer awareness, trial and adoption of Truvia® products in the U.S. Since opening the U.S. market for stevia-based sweeteners in 2008, the Truvia® brand has led the natural sweetener category and now holds a 61 percent market share.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58203-truvia-from-nature-for-sweetness-campaign-spotlights-stevia-sweetener
Sutter Neuroscience Institute, a recognized Center of Excellence, and CBR (Cord Blood Registry), the world’s largest stem cell bank, are launching the first FDA- approved clinical trial to assess the use of a child’s own cord blood stem cells to treat select patients with autism. This first-of-its-kind placebo controlled study will evaluate the ability of an infusion of cord blood stem cells to help improve language and behavior. The study is in conjunction with the Sutter Institute for Medical Research.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57707-cord-blood-registry-stem-cell-trials-child-autism
Software just changed the way of our work. First, computer came and changes the technology. Then, Internet changed our way to look for anything and now, hundreds of software launched each day to make our work easier on computers. Number of IT companies from all over the world just keep on developing kind of software which human beings had dream last night and what he got next day. In latest software release news, the software already available on Internet and many of users already gone through all its working. Advanced technology and much explore of human brains made this thing look very easy.
Software somehow makes our work much easier on our working machines. Internet becomes the source to get any software instant if available. Most of the software on the Internet available without any cost and some of them want you to pay before use. Among most of the categories, we mostly come up with two kinds, Commercial and Open Source software. Now, what these kind of software?
Let me to explain about these software types:-
Open Source Software:- Open Source software are those kind of software which requires no cost to use them and anyone seek any kind of improvement software need can improve it and again, launch with its improved version on Internet. Again, another user can add some extra features to that software and launch on the Internet. Programming code for open source software easily available on Internet.
Commercial Software: - Open Source software can also be commercial software. Commercial software used as commercial purposes. Some of this software is available on the Internet for free, while some named software you can also get for free but on a trial period maximum of 30 days. After 30 days of use, you have to purchase the software license. Microsoft, Adobe etc all among these commercial software production companies. Some of the best commercial software made by these multinational companies are MS Office, Adobe Photoshop, Adobe Flash player etc.
Take Linux as most appropriate example. Linux was first launched in 1991 and now, a number of improved versions available on the Internet. Linux is completely open source operating system software. If you have some knowledge about software and want to add some extra features, you can easily do it. Most of the companies currently have Linux as there operating system rather than Windows XP, Windows Vista or Windows 7 because Linux is much easier to operate and occupied less space, light in use. Now, take a look on Adobe Photoshop. You want to make an image, website, background image with some special effects etc, you need to have knowledge about Adobe Photoshop and its various features.
This commercial software somehow available without any cost on Internet but you just cannot go for all its features. You want to use all its features, go and purchase a license. But you do not need to pay for open source software.
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Audi stellt ab dem 16. Mai am Wörthersee in Kärnten ein außerordentlich emotionales Sportgerät vor. Das Audi e-bike Wörthersee vereint Elektroantrieb und Muskelkraft. Design-Chef Wolfgang Egger: „Als High-Performance E-Bike für Sport und Tricks bündelt es die Audi-Kernkompetenzen design, ultra, e-tron und connect.“ Bei der diesjährigen Wörthersee-Tour, dem 31. Treffen der Audi-, VW-, Seat- und Skoda-Fans, hat das E-Bike seine Weltpremiere: Trial-Biker Julien Dupont und Downhill-Spezialistin Petra Bernhard demonstrieren ihre Stunt- und Streetbike-Fähigkeiten.
http://multivu.prnewswire.com/mnr/prne/audi/53820/
In collaboration with the National Institutes of Health (NIH), Banner Alzheimer’s Institute (BAI), University of Antioquia in Colombia and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announce the first-ever prevention trial in cognitively healthy individuals who are destined to develop Alzheimer’s disease because of their genetic history. This groundbreaking study—the first to investigate whether an anti-amyloid treatment can stave off the disease—will span two countries and help launch a new era of prevention research in the urgent fight against Alzheimer’s.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56128-banner-alzheimer-s-institute-genentech-nih-prevention-trial-genetics
